Galmed Pharmaceuticals Ltd.
GLMD · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $1,086 | $1,058 | $634 | $1,072 |
| G&A Expenses | $1,009 | $1,051 | $630 | $572 |
| SG&A Expenses | $1,009 | $1,051 | $630 | $572 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $2,095 | $2,109 | $1,264 | $1,644 |
| Operating Income | -$2,095 | -$2,109 | -$1,264 | -$1,565 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $203 | -$386 | $160 | -$1,644 |
| Pre-Tax Income | -$1,892 | -$2,495 | -$1,104 | -$3,209 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1,892 | -$2,495 | -$1,104 | -$3,209 |
| % Margin | – | – | – | – |
| EPS | -0.35 | -0.63 | -0.62 | -46.42 |
| % Growth | 44.4% | -1.6% | 98.7% | – |
| EPS Diluted | -0.35 | -0.63 | -0.62 | -46.42 |
| Weighted Avg Shares Out | 5,460 | 3,948 | 1,780 | 1,607 |
| Weighted Avg Shares Out Dil | 5,460 | 3,948 | 1,780 | 1,607 |
| Supplemental Information | – | – | – | – |
| Interest Income | $203 | $140 | $160 | $0 |
| Interest Expense | $0 | $0 | $0 | $448 |
| Depreciation & Amortization | $21 | $0 | $0 | $1,565 |
| EBITDA | -$2,074 | -$2,109 | -$1,264 | -$1,644 |
| % Margin | – | – | – | – |